NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
TSX · APTX.TO · CAD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Apotex Health Corp.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of CA$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Apotex Health Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. It operates through three business lines including conventional generic pharmaceuticals; specialty generic pharmaceuticals; and brands & biosimilars. The company has a a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. Apotex Health Corp. was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CA$11.40+CA$0.09 (+0.8%)
Knight Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.63% below the high.
